Peptide News Digest

#1-46-Billion-Chf

2 stories

Industry · View digest

Samsung Peptide AG Publishes Formal Tender Offer Prospectus for PolyPeptide Group AG; Offer Period September 15 to October 12, 2026

Samsung Biologics (KRX: 207940), through its Swiss subsidiary Samsung Peptide AG, published Monday August 31, 2026 the formal tender offer prospectus for all publicly held registered shares of PolyPeptide Group AG (SIX: PPGN) on SIX Swiss Exchange. Terms: CHF 44.31 net in cash per share (implied equity value approximately CHF 1.46 billion / $1.8 billion, a 40% premium to the CHF 31.65 undisturbed share price of April 10, 2026). The cooling-off period runs 10 SIX trading days from September 1, and the main offer period commences September 15, 2026 through October 12, 2026 at 4 p.m. Swiss time. Draupnir Holding B.V. (approximately 55.65% of PolyPeptide shares) has committed to tender all shares. Closing conditions include a 66⅔% minimum acceptance threshold plus customary regulatory approvals; transaction close is targeted for end of 2026. Samsung intends to squeeze out remaining minorities and delist PolyPeptide post-close, integrating the Malmö, Limhamn, Strasbourg, Braine-l'Alleud, and Torrance sites into the Incheon multi-modality biologics footprint.

Industry · View digest

Samsung Biologics PolyPeptide Tender Offer Prospectus Set to Publish by End of August, 20 Trading Day Offer Period

Samsung Biologics' $1.8 billion (CHF 1.46 billion) all-cash tender offer for Swiss peptide CDMO PolyPeptide Group (SIX: PPGN) is scheduled to publish the formal offer prospectus by the end of August 2026, following the mandatory 10 trading-day cooling-off period under Swiss takeover law. Terms: CHF 44.31 per share (40% premium to the CHF 31.65 undisturbed price on April 10, 2026). The offer will run for a minimum of 20 trading days on SIX Swiss Exchange and is conditioned on at least 66⅔% of shares tendered on a fully diluted basis plus customary regulatory approvals. Deal close is targeted for end of 2026, after which Samsung intends to squeeze out remaining minorities and delist PolyPeptide. The transaction would give Samsung Biologics one of the top three peptide CDMO capacity positions globally, integrated with Samsung's existing multi-modality biologics network across the U.S., Europe, and India.